Revenue Recognition (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended			12 Months Ended
	Jul. 31, 2021	Feb. 28, 2019	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2019	Aug. 31, 2019
Refunds of revenues previously deferred				$ 10,000
Deferred revenue, Long-term			$ 20,543					$ 21,318
Other assets			21,676					18,820
Deferred revenue			34,457	32,885				28,722	$ 72,930
Deferred revenue, current portion			13,914					7,404
Total revenues			194,133	152,316
Deferred revenue, long-term portion			20,543					21,318
Revenue recognized during the period that was included in deferred revenues at the beginning of the period			3,889	30,292
Product
Revenue recognized			1,400	1,300
Cost of revenues			102,670	65,832
Total revenues			$ 190,002	120,384
Product | Minimum
Billing collection period (in months)			9 months
Product | Maximum
Billing collection period (in months)			12 months
Licensing and other
Cost of revenues			$ 545	981
Total revenues			4,131	31,932
Genetic testing services
Revenue recognized during the period that was included in deferred revenues at the beginning of the period			$ 100
Qiagen
Proceeds from license agreement							$ 5,000
Agreement term			10 years
Revenue, remaining performance obligation							40,000
Qiagen | Volume, regulatory and commercial milestones
Revenue, remaining performance obligation							$ 10,000
Qiagen | Other licensing and other revenue
Refunds of revenues previously deferred				10,000
Deferred revenue				$ 28,600
Laboratory distribution partners | Product | Minimum
Billing collection period (in months)			2 months
Laboratory distribution partners | Product | Maximum
Billing collection period (in months)			3 months
BGI Genomics
Proceeds from license agreement		$ 50,000			$ 35,600
Receivable					$ 2,500
Agreement term		10 years
Deferred revenue, current portion			$ 7,500
BGI Genomics | Sequencing services
Other assets										$ 6,000
BGI Genomics | Sequencing products
Other assets										4,000
BGI Genomics | Sequencing products and services
Other assets										$ 10,000
BGI Genomics | Milestone payments
Receivable			5,000
Foundation Medicine ("FMI")
Proceeds from license agreement						$ 16,300
Deferred revenue, current portion			1,600
Foundation Medicine ("FMI") | Milestone payments
Proceeds from license agreement	$ 1,000
Receivable			2,000
Deferred revenue, current portion			$ 1,000					$ 2,000
Foundation Medicine ("FMI") | Upfront licensing fees and prepaid revenues
Initial transaction price											$ 13,300
Foundation Medicine ("FMI") | Developmental, regulatory, and commercial milestones
Initial transaction price											$ 32,000
Foundation Medicine ("FMI") | Developmental performance milestones
Proceeds from license agreement						3,000
Foundation Medicine ("FMI") | Licensing fees and prepaid revenue
Proceeds from license agreement						$ 13,300